2-氯-4-甲氧基烟酸 | 394729-98-7

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-氯-4-甲氧基烟酸
• 中文别名: 2-氯-4-甲氧基吡啶-3-甲酸
• 英文名称: 2-chloro-4-methoxynicotinic acid
• 英文别名: 2-Chloro-4-methoxynicotinic acid；2-chloro-4-methoxypyridine-3-carboxylic acid
• CAS: 394729-98-7
• 化学式: C₇H₆ClNO₃
• 分子量: 187.583
• InChiKey: ZBHVWHBZHRBHRQ-UHFFFAOYSA-N

物化性质

• 熔点：
  170-176 °C (decomp)
• 沸点：
  339.4±37.0 °C(Predicted)
• 密度：
  1.430±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  59.4
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  2-氯-4-甲氧基烟酸 在 三乙基硅烷 、 草酰氯 、 间氯过氧苯甲酸 、 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 、 氯仿 、 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 4-methoxy-9-(4-methoxybenzylamino)-5-[2-(4-methoxybenzylamino)pyrimidin-4-yl]pyrido[3',2':4,5]pyrrolo[1,2-c]pyrimidine
  参考文献：
  名称：

  水痘蛋白B的全合成

  摘要：

  从市售的4-氯-2-甲基硫代嘧啶开始，海洋生物碱variolin B的总合成已通过八个步骤完成。关键反应涉及使用三乙基硅烷和三氟乙酸的组合进行三芳基甲醇的串联脱氧和环化反应。

  DOI：

  10.1016/s0040-4039(01)01881-0
• 作为产物：
  描述：

  4-methoxy-2-chloronicotinic acid ethyl ester 在 sodium hydroxide 作用下， 反应 0.5h， 以1.49 g的产率得到2-氯-4-甲氧基烟酸
  参考文献：
  名称：

  Concise Total Syntheses of Variolin B and Deoxyvariolin B

  摘要：

  The total synthesis of the marine alkaloid variolin B has been achieved in 8 steps and 17% overall yield, starting from commercially available 4-chloro-2-methylthiopyrimidine. The key reaction involves the tandem deoxygenation and cyclization of a triarylmethanol using a combination of triethylsilane and trifluoroacetic acid. In addition, the deoxygenated analogue was prepared in 6 steps and 23% overall yield, starting from the same starting material.

  DOI：

  10.1021/jo050523v

文献信息

• [EN] PYRROLIDINE OREXIN RECEPTOR ANTAGONISTS<br/>[FR] COMPOSÉS PYRROLIDINE EN TANT QU'ANTAGONISTES DU RÉCEPTEUR DE L'HYPOCRÉTINE
  申请人：MERCK SHARP & DOHME

  公开号：WO2016095204A1

  公开（公告）日：2016-06-23

  The present invention is directed to pyrrolidine compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及对促进素受体的拮抗剂吡咯烷化合物。本发明还涉及所述化合物在潜在的治疗或预防涉及促进素受体的神经和精神疾病和疾病中的用途。本发明还涉及包含这些化合物的组合物。本发明还涉及这些组合物在潜在的预防或治疗涉及促进素受体的疾病中的用途。
• SUBSTITUTED PYRIDOBENZODIAZEPINONE-DERIVATIVES AND USE THEREOF
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：US20170253602A1

  公开（公告）日：2017-09-07

  The present application relates to novel (3-hydroxyphenyl)amino-substituted pyrido[2,3-b][1,5]benzodiazepin-5-one derivatives, to processes for preparation thereof, to the use thereof alone or in combination for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially of angiogenic disorders and hyperproliferative disorders in which neovascularization plays a role, for example ophthalmological disorders and cancers and tumours. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.

  本申请涉及新型(3-羟基苯基)氨基取代的吡啶并[2,3-b][1,5]苯二氮杂二环己酮衍生物，以及其制备方法，单独或联合用于治疗和/或预防疾病的用途，以及用于生产用于治疗和/或预防疾病的药物的用途，特别是对血管生成障碍和细胞过度增殖障碍的治疗，其中新生血管化起作用，例如眼科疾病和癌症和肿瘤。这种治疗可以作为单独治疗或与其他药物或进一步治疗措施结合使用。
• Compounds and methods of use
  申请人：Germain Julie

  公开号：US20070185171A1

  公开（公告）日：2007-08-09

  Selected compounds are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  所选化合物对于预防和治疗血管生成介导的疾病等疾病有效。该发明涵盖了新颖的化合物、类似物、前药和其药学上可接受的盐、药物组合物以及预防和治疗癌症等涉及疾病和其他疾病或病况的方法。该发明还涉及制造这种化合物的过程以及在这种过程中有用的中间体。
• Pyrrolidine orexin receptor antagonists
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10150751B2

  公开（公告）日：2018-12-11

  The present invention is directed to pyrrolidine compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及作为奥曲肽受体拮抗剂的吡咯烷化合物。本发明还涉及本文所述化合物在潜在治疗或预防涉及奥曲肽受体的神经和精神疾病中的用途。本发明还涉及包含这些化合物的组合物。本发明还涉及这些组合物在潜在预防或治疗涉及奥曲肽受体的此类疾病中的用途。
• Design, Synthesis, Bioactivity, and Tentative Exploration of Action Mode for Benzyl Ester-Containing Derivatives
  作者：Qinglong Yuan、Wen Fu、Xiaoyan Li、Zhiping Xu、Xili Liu、Zhong Li、Xusheng Shao

  DOI：10.1021/acs.jafc.4c01033

  日期：2024.7.24

  molecules (Y1–Y53) containing chloro-substituted benzyl esters were designed using the above strategy. The structure–activity relationship (SAR) analysis demonstrated that the fatty acid fragment-structured esters were more effective than those containing an aromatic acid moiety or naphthenic acid part. Compounds Y36 and Y41, which featured a thiazole-4-acid moiety and trifluoromethyl aliphatic acid part

  主动剪接策略见证了农药发现中生物活性和抗真菌谱的改善。在此，使用上述策略设计了一系列含有氯取代苄酯的简单结构分子（ Y1 - Y53 ）。构效关系（SAR）分析表明，脂肪酸片段结构的酯比含有芳香酸部分或环烷酸部分的酯更有效。化合物Y36和Y41分别具有噻唑-4-酸部分和三氟甲基脂肪酸部分，表现出优异的体内治疗活性（89.4％，100mg/L Y36 ）和体外杀菌活性（EC 50 = 0.708mg/L）。 L， Y41 ) 对抗灰葡萄孢。抗真菌谱的测定以及扫描电子显微镜（SEM）、膜通透性、细胞过氧化、麦角甾醇含量、草酸途径和酶测定的分析在此单独进行。化合物Y41由于其简单的结构而具有成本效益，并且显示出作为疾病控制候选药物的前景。此外， Y41可能通过诱导细胞过氧化破坏细胞膜完整性的新途径作用于新靶点。